Efficacy of the Enteroadsorbent Silicol®gel in Adults with Irritable Bowel Syndrome Subtypes IBS-D or Mixed: Observational Open-Label Study

Overview

Journal Gastroenterol Res Pract

Publisher Wiley

Specialty Gastroenterology

Date 2024 Sep 12

PMID 39263347

Authors

Gordon Crawford

Rory Taylor

David Young

Chris G Hatton

Affiliations

Soon will be listed here.

Abstract

Background: Irritable bowel syndrome (IBS) is a common chronic gut-brain interaction disorder with limited effective treatment options. Intestinal adsorbents have a high adsorption capacity for gut irritants and may provide nonpharmacological alternatives.

Objectives: This post marketing study is aimed at providing up-to-date evidence to support the safety and efficacy in normal use of an established medical device for IBS treatment.

Methods: In this open-label, observational study, adults with IBS with predominant diarrhoea (IBS-D) or IBS with mixed bowel habits (IBS-M), according to Rome IV criteria, received 4 weeks of treatment with the enteroadsorbent Silicol®gel, a CE-certified, licenced, medical device containing colloidal silicic acid. Eligible participants were assessed at baseline (visit 1; in-clinic) and after 1 (visit 2; telephone), 2 (visit 3; telephone), and 4 (visit 4; in-clinic) weeks of treatment. The primary endpoint was the proportion of participants with an overall reduction in the IBS severity scoring system (IBS SSS) > 50, representing clinically meaningful improvement. Key secondary endpoints were a reduction in common IBS symptoms and improved quality of life (QoL).

Results: Among the 67 treated participants (IBS-D: 37; IBS-M: 30), 65 completed the study. At visit 4, 83.6% (56/67) of participants achieved a reduction in IBS SSS > 50. The mean (standard deviation [SD]) IBS SSS was 323.4 (55.7) at visit 1 and 160.3 (90.3) at visit 4 (overall change: -163.1 (101.7); 95% confidence interval [CI] 138.3, 187.9, < 0.001). Compared with visit 1, significant reductions in the severity of all key IBS symptoms and overall improvement in QoL were observed at visit 4 ( < 0.001), with improvements observed from visits 1 and 2.

Conclusions: In this open-label study of participants with IBS-D and IBS-M, Silicol®gel provided clinically significant improvement in IBS symptoms, demonstrating that enteroadsorbents may be clinically beneficial in this population.

References

Berman S, Naliboff B, Suyenobu B, Labus J, Stains J, Ohning G . Reduced brainstem inhibition during anticipated pelvic visceral pain correlates with enhanced brain response to the visceral stimulus in women with irritable bowel syndrome. J Neurosci. 2008; 28(2):349-59. PMC: 6670525. DOI: 10.1523/JNEUROSCI.2500-07.2008. View

Park G, Spector R, Goldberg M, JOHNSON G . Expanded role of charcoal therapy in the poisoned and overdosed patient. Arch Intern Med. 1986; 146(5):969-73. View

Shah E, Pimentel M . Placebo effect in clinical trial design for irritable bowel syndrome. J Neurogastroenterol Motil. 2014; 20(2):163-70. PMC: 4015207. DOI: 10.5056/jnm.2014.20.2.163. View

Chang F, Lu C, Chen C, Luo J . Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome. J Gastroenterol Hepatol. 2007; 22(12):2266-72. DOI: 10.1111/j.1440-1746.2007.04895.x. View

Yiannakou Y, Agrawal A, Allen P, Arebi N, Brown S, Eugenicos M . UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation. Therap Adv Gastroenterol. 2018; 11:1756284818798791. PMC: 6170957. DOI: 10.1177/1756284818798791. View

Lakhan S, Kirchgessner A . Gut inflammation in chronic fatigue syndrome. Nutr Metab (Lond). 2010; 7:79. PMC: 2964729. DOI: 10.1186/1743-7075-7-79. View

Enck P, Aziz Q, Barbara G, Farmer A, Fukudo S, Mayer E . Irritable bowel syndrome. Nat Rev Dis Primers. 2016; 2:16014. PMC: 5001845. DOI: 10.1038/nrdp.2016.14. View

Rateau J, Morgant G, Parier J . A histological, enzymatic and water-electrolyte study of the action of smectite, a mucoprotective clay, on experimental infectious diarrhoea in the rabbit. Curr Med Res Opin. 1982; 8(4):233-41. DOI: 10.1185/03007998209109772. View

Ford A, Moayyedi P, Chey W, Harris L, Lacy B, Saito Y . American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2018; 113(Suppl 2):1-18. DOI: 10.1038/s41395-018-0084-x. View

10.

Goodoory V, Ng C, Black C, Ford A . Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom. Aliment Pharmacol Ther. 2022; 56(1):110-120. PMC: 9325446. DOI: 10.1111/apt.16939. View

11.

Lovell R, Ford A . Prevalence of gastro-esophageal reflux-type symptoms in individuals with irritable bowel syndrome in the community: a meta-analysis. Am J Gastroenterol. 2012; 107(12):1793-801. DOI: 10.1038/ajg.2012.336. View

12.

Min Y, Rhee P . The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D). Therap Adv Gastroenterol. 2015; 8(3):136-42. PMC: 4416292. DOI: 10.1177/1756283X15572580. View

13.

Piacentino D, Cantarini R, Alfonsi M, Badiali D, Pallotta N, Biondi M . Psychopathological features of irritable bowel syndrome patients with and without functional dyspepsia: a cross sectional study. BMC Gastroenterol. 2011; 11:94. PMC: 3175195. DOI: 10.1186/1471-230X-11-94. View

14.

Guss D . Emergency medicine: activated charcoal-the first-line agent in cases of overdose. West J Med. 1989; 151(1):63. PMC: 1026954. View

15.

Passos M, Lembo A, Conboy L, Kaptchuk T, Kelly J, Quilty M . Adequate relief in a treatment trial with IBS patients: a prospective assessment. Am J Gastroenterol. 2009; 104(4):912-9. PMC: 2707022. DOI: 10.1038/ajg.2009.13. View

16.

Ballou S, Keefer L . The impact of irritable bowel syndrome on daily functioning: Characterizing and understanding daily consequences of IBS. Neurogastroenterol Motil. 2016; 29(4). PMC: 5367953. DOI: 10.1111/nmo.12982. View

17.

Howell C, Markaryan E, Allgar V, Kemppinen A, Khovanov A, Pandya P . Enterosgel for the treatment of adults with acute diarrhoea in a primary care setting: a randomised controlled trial. BMJ Open Gastroenterol. 2019; 6(1):e000287. PMC: 6505981. DOI: 10.1136/bmjgast-2019-000287. View

18.

Flacco M, Manzoli L, De Giorgio R, Gasbarrini A, Cicchetti A, Bravi F . Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a meta-analysis. Eur Rev Med Pharmacol Sci. 2019; 23(7):2986-3000. DOI: 10.26355/eurrev_201904_17580. View

19.

Sperber A, Bangdiwala S, Drossman D, Ghoshal U, Simren M, Tack J . Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2020; 160(1):99-114.e3. DOI: 10.1053/j.gastro.2020.04.014. View

20.

Everitt H, Landau S, Little P, Bishop F, OReilly G, Sibelli A . Therapist telephone-delivered CBT and web-based CBT compared with treatment as usual in refractory irritable bowel syndrome: the ACTIB three-arm RCT. Health Technol Assess. 2019; 23(17):1-154. PMC: 6545494. DOI: 10.3310/hta23170. View